During primary total knee arthroplasty, use of a hemostatic agent led to decreased calculated blood loss and drain output but did not lead to reduced transfusion requirements, according to study results.
In a prospective, single-center study, researchers randomly assigned 108 patients to a hemostatic matrix treatment group or to a control group. The primary outcome measure was calculated blood loss, and secondary outcomes measures were transfusion requirements, hemoglobin loss, drain output and length of stay.
Study results showed a statistically significant difference in calculated blood loss and drain output among the two groups, favoring patients who received the hemostatic agent; however, no statistically significant difference was seen in transfusion requirements or mean hemoglobin loss, according to the researchers.
The researchers also found no significant difference among hemoglobin or hematocrit drip, postoperative fluids or hidden blood loss between the groups.
Patients treated with the hemostatic agent had a slightly shorter length of stay, according to the researchers.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.